Trial
NCT02404506
Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Breast Cancer
Intervention
Eribulin mesilate
Why stopped
The trial was prematurely terminated as of 22.07.2021 as per SAKK board decision board decision from 14th of November 2020. The trial was terminated after the primary endpoint was analyzed, which was the case end of December 2020.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-29